

## Minireview

# Clinical anticancer drug development: targeting the cyclin-dependent kinases

C Benson<sup>1</sup>, S Kaye<sup>1</sup>, P Workman<sup>1</sup>, M Garrett<sup>1</sup>, M Walton<sup>1</sup> and J de Bono<sup>\*,1</sup>

<sup>1</sup>Section of Medicine and Cancer Research UK Centre for Cancer Therapeutics, Institute for Cancer Research and Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK

Cell division involves a cyclical biochemical process composed of several step-wise reactions that have to occur once per cell cycle. Dysregulation of cell division is a hallmark of all cancers. Genetic and epigenetic mechanisms frequently result in deranged expression and/or activity of cell-cycle proteins including the cyclins, cyclin-dependent kinases (Cdks), Cdk inhibitors and checkpoint control proteins. The critical nature of these proteins in cell cycling raises hope that targeting them may result in selective cytotoxicity and valuable anticancer activity.

*British Journal of Cancer* (2005) **92**, 7–12. doi:10.1038/sj.bjc.6602229 www.bjcancer.com

Published online 23 November 2004

© 2005 Cancer Research UK

**Keywords:** cell cycle; targeted therapy

## STRATEGIES FOR TARGETING THE CELL CYCLE

Dysregulation of the cell cycle is a hallmark of malignancy (Table 1). Many different strategies for targeting the cell cycle have been described. Attention has focused primarily on targeting mitosis (by targeting tubulin and more recently mitotic kinases including KSP/Eg5, Polo-like kinase 1 and Aurora kinases) as well as chemical inhibitors of cyclin-dependent kinase (Cdk) catalytic activity. Other potential strategies include therapeutics that can inhibit the interaction between cyclins and Cdks; decrease cyclin expression; promote the degradation of cyclins by increasing their phosphorylation; and restore endogenous Cdk inhibitor function. Other possibilities include the inhibition of the 'noncycling' cyclin-activating kinase complex of Cdk7/cyclin H, and the indirect targeting of the late G2 to M checkpoint by inhibiting CDC25 or by activating WEE1 or MYT1. This review will, however, focus on the chemical Cdk inhibitors evaluated in clinical trials to date and will highlight the main trial results reported to date.

## PHARMACOLOGIC CDK INHIBITORS

Considerable progress has been made in the identification of pharmacologic agents targeting the Cdks (Senderowicz, 2003). The first generation of Cdk inhibitors lacked specificity, with flavopiridol, staurosporine and its analogue UCN-01 and E7070 being nonselective inhibitors of not only Cdks but many other targets. Second-generation inhibitors are more selective, with many of these compounds specifically developed to target selected Cdks (Table 2).

## Flavopiridol

Flavopiridol (Alvocidib™) has several mechanisms of anticancer activity (Senderowicz and Sausville, 2000) and is a broad-spectrum Cdk inhibitor targeting Cdks 1, 2, 4, 6 and 7, interacting with the adenosine triphosphate (ATP) binding site. Flavopiridol also inhibits the Cdk9/cyclin T complex, broadly repressing transcription and decreasing cyclin D1 mRNA expression (Carlson *et al*, 1999). It induces cell-cycle arrest in G1 and is cytotoxic to cells undergoing DNA synthesis. It also inhibits other kinases including PKC and PKA at higher concentrations, inducing apoptosis, (Patel *et al*, 1998) and is active in many xenograft models.

The first Phase I trial of flavopiridol utilised a 72-h continuous infusion every 2 weeks, a schedule supported by preclinical models (Senderowicz *et al*, 1998). The maximum-tolerated dose (MTD) achieved in this clinical trial was 50 mg m<sup>2</sup> day<sup>-1</sup>, the initial dose-limiting toxicity being secretory diarrhoea. The MTD with antidiarrhoeal prophylaxis was 78 mg m<sup>2</sup> day<sup>-1</sup> (Kahn *et al*, 2001; Messmann *et al*, 2003). The achieved plasma levels were sufficient for Cdk inhibition (200–400 nM), with one partial response in renal cell cancer and minor responses in renal, colorectal carcinomas and non-Hodgkin's lymphoma.

This 72-h schedule was subsequently investigated in further Phase I and Phase II trials in patients with mantle cell lymphoma, renal cancer, melanoma, gastric cancer, non-small-cell lung cancer (NSCLC) and colorectal cancers (Bennett *et al*, 1999; Stadler *et al*, 2000; Schwartz *et al*, 2001; Shapiro *et al*, 2001; Lin *et al*, 2002; Thomas *et al*, 2002). An unusually high incidence of arterial and venous thromboembolic events was documented in the majority of these trials, including deep venous thrombosis, pulmonary thromboembolism, myocardial infarction and transient neurological ischaemic events. This serious drug-related toxicity was not appreciated in the initial studies but was reported in more than 30% of patients in later trials and is of unknown aetiology.

\*Correspondence: Dr JS de Bono; E-mail: johanndebono@hotmail.com  
Received 23 June 2004; revised 7 October 2004; accepted 11 October 2004; published online 23 November 2004

**Table 1** (a) Deregulated cyclins and Cdk's and associated tumours and (b) deregulated endogenous Cdk inhibitors and associated tumours

Target	Oncogenic changes	Associated tumours
<i>(a)</i>		
Cyclin D1	Gene amplification Overexpression Translocation	40–80% Breast carcinoma 70% Familial polyposis 50% B-cell lymphoma 50% NSCLC 35% Head and neck carcinoma 25–50% Oesophageal carcinoma 25% Bladder carcinoma
Cyclin E	Gene amplification Overexpression	90% Colorectal carcinoma 30–80% Breast carcinoma 70% Prostate carcinoma 18% Ovarian carcinoma Gastric carcinoma Cervical carcinoma
Cyclin E2	Overexpression	Breast carcinoma Small-cell lung carcinoma Cervical carcinoma
Cyclin B1	Overexpression	90% Colorectal carcinoma
Cyclin A	Amplification or overexpression	Hepatocellular carcinoma
CDK2	Overexpression	Colorectal carcinoma
CDK4	Amplification	Sarcomas, gliomas
<i>(b)</i>		
p16 <sup>INK4a</sup>	Mutation (5% of human cancers) Deletion (14% of human cancers) Epigenetic (19% of human cancers)	Pancreatic cancer Melanoma Gliomas Bladder cancer Head and neck cancer NSCLC Lymphoma/leukaemia
p21 <sup>cip-1</sup> / waf-1	Mutation/deletion rare  Downregulation rare Intracellular mislocalisation <sup>a</sup>	Oral (rare mutations)  Oesophageal (rare mutations) Breast (rare mutations)
p27 <sup>kip-1</sup>	Mutations/deletions rare Downregulation (increased degradation) <sup>a</sup>	Breast <sup>a</sup> Colon <sup>a</sup>  Prostate <sup>a</sup>

NSCLC = non-small-cell lung cancer. <sup>a</sup>Increased degradation.

A study of flavopiridol administered as a 1-h infusion was then pursued supported by data indicating that higher plasma concentrations than those achieved in the 72-h infusion studies were required to induce apoptosis (Arguello *et al*, 1998; Tan *et al*, 2002). Initially, a 1-h infusion administered for 5 days every 3 weeks was investigated. The recommended Phase II dose for this schedule was 37.5 mg m<sup>2</sup> day<sup>-1</sup>, with grade 4 neutropenia and grade 3 fatigue being dose limiting. The three- and one-day schedules administered every 3 weeks were also evaluated with the aim of further increasing peak serum levels of drug. Grade 4 neutropenia was also dose limiting in these studies, with the recommended Phase II dose of these schedules being 50 mg m<sup>2</sup> day<sup>-1</sup> and 62.5 mg m<sup>-2</sup>, respectively. The peak plasma concentrations, however, remained lower than the concentrations required in preclinical studies to induce apoptosis (5–7 μmol l<sup>-1</sup>), with no objective tumour responses being observed. Phase II studies of flavopiridol administered by 1-h infusion daily for 3 days every 3 weeks have been reported. No responses were observed in advanced melanoma (Burdette-Radoux *et al*, 2002); however, in patients with advanced mantle cell lymphoma, three

responses out of 28 evaluable patients (11%) were reported, with 20 patients having stable disease (71%) for a median duration of 3.4 months (Kouroukis *et al*, 2003).

An alternative administration schedule has been recently evaluated for flavopiridol in patients with chronic lymphatic leukaemia. Previous Phase I/II studies had shown that, while flavopiridol induces apoptosis in CLL cells in a p53-independent manner *in vitro*, the drug is inactive using a 24- to 72-h CIVI schedule. Based on pharmacokinetic modelling data demonstrating high drug binding to human plasma proteins, an optimised dosing schedule of 30-min i.v. bolus (IVB) followed by 4-h CIVI has been pursued. This alternative schedule has demonstrated promising activity including flavopiridol-induced tumour lysis syndrome, suggesting that this agent may warrant further evaluation using this novel schedule (Lin *et al*, 2004).

The use of flavopiridol in combination studies has also been pursued (Bible and Kaufmann, 1997; Motwani *et al*, 2001). Treatment scheduling appears to be important in ensuring that flavopiridol augments the effects of other agents (Schwartz *et al*, 2002; Wittmann *et al*, 2003).





## UCN-01

The second chemical Cdk inhibitor to be evaluated was UCN-01 (7-hydroxystaurosporine) (Senderowicz and Sausville, 2000), which also has several mechanisms of action including Cdk1 (cdc2) and Cdk2 inhibition (IC<sub>50</sub> of 300–600 nM). UCN-01 causes cell-cycle arrest and apoptosis at concentrations above 100 nM (Akiyama *et al*, 1997), abrogating the G<sub>2</sub> checkpoint in response to DNA damage and promoting the induction of p53-independent apoptosis by inhibiting Chk1 and Chk2 (IC<sub>50</sub> for both approximately 10–30 nM). (Wang *et al*, 1996; Busby *et al*, 2000; Yu *et al*, 2002). UCN-01 also abrogates S-phase arrest in CHO cells treated with cisplatin, promoting the induction of apoptosis (Bunch and Eastman, 1997), and may target Akt signalling by inhibiting PDK1 (IC<sub>50</sub> = 33 nM) (Sato *et al*, 2002). Frequent dosing is required to optimise the antitumour activity of UCN-01 (Sausville *et al*, 1998), and 72 h of drug exposure is required to achieve growth inhibition. A Phase I trial of UCN-01 administered as a 72-h continuous infusion every 2 weeks to patients with advanced malignancy revealed long elimination half-lives due to high-affinity binding of UCN-01 to α1-acid glycoprotein in human plasma (Fuse *et al*, 1998; Sausville *et al*, 2001). This schedule was therefore changed to a 72-h continuous infusion administered every 4 weeks, with a recommended dose of 42.5 mg m<sup>2</sup> day<sup>-1</sup>. Dose-limiting toxicities at 53 mg m<sup>-2</sup> included hyperglycaemia, pulmonary toxicity with hypoxaemia, emesis and hypotension. The basis for the pulmonary toxicity was unclear but did not involve altered cardiac motility or pulmonary thromboembolism, being associated with small, transient, pleural effusions. Hyperglycaemia occurred at all dose levels. Analysis of immunoreactive C peptide levels suggested that this was related to peripheral tissue insulin resistance rather than a decrease in insulin secretion. Pharmacokinetic analysis revealed a terminal half-life of 588 h, with mean drug plasma concentrations in the micromolar range. Analysis of free salivary levels of UCN-01 showed drug levels of approximately 100 nM, which is sufficient to affect cell-cycle parameters *in vitro*. A partial response of 6 months duration was observed in patient with melanoma, and a complete response, sustained for over 38 months in a patient with anaplastic large-cell lymphoma.

## E7070

E7070 is a chloroindolyl sulphonamide that induces G1/S cell cycle arrest at low nanomolar concentrations, inhibiting Cdk2/cyclin E, downregulating cyclin H, upregulating p53 and p21, and inducing

**Table 2** Chemical Cdk inhibitors and their targets

Cdk Inhibitors in the Clinic			
			
<b>Flavopiridol</b>	<b>R-Roscovotine (CYC-202)</b>	<b>BMS 387032</b>	<b>UCN01</b>
Cdk1/B IC <sub>50</sub> = 0.03 μM	Cdk1/B IC <sub>50</sub> =2.69 μM	Cdk1/B IC <sub>50</sub> =0.481 μM	Cdk1/B IC <sub>50</sub> = 0.3 μM
Cdk2/E IC <sub>50</sub> = 0.17 μM	Cdk2/E IC <sub>50</sub> =0.10 μM	Cdk2/E IC <sub>50</sub> =0.048 μM	Cdk2/E IC <sub>50</sub> = 0.3 μM
Cdk4/D IC <sub>50</sub> = 0.10 μM	Cdk4/D IC <sub>50</sub> = 14.21 μM	Cdk4/D IC <sub>50</sub> =0.925 μM	PKC IC <sub>50</sub> =0.03 μM
Cdk9/T IC <sub>50</sub> < 0.010 μM <sup>a</sup>	Cdk7/H IC <sub>50</sub> = 0.5 μM <sup>a</sup>		Chk1 IC <sub>50</sub> =0.011 μM
	Cdk9/T1 IC <sub>50</sub> =0.8 μM <sup>a</sup>		Chk2 IC <sub>50</sub> = 1.04 μM

<sup>a</sup>Increased degradation downregulate transcription, for example, ↓ cyclin D1 expression.

apoptosis (Ozawa *et al*, 2001). Its potency is enhanced by longer drug exposures (Ozawa *et al*, 2001). E7070 has a broad spectrum of *in vitro* and *in vivo* preclinical antitumour activity, inducing regression of established tumours. This efficacy is schedule dependent, with a daily-for-8-days schedule being more efficacious than 4- and 1-day schedules.

A number of Phase I trials of this agent have been performed investigating different dosing regimens. When given daily by intravenous infusion for 5 days every 3 weeks, the DLTs consisted of neutropenia, thrombocytopenia, diarrhoea and stomatitis, with a recommended Phase II dose of 130 mg m<sup>-2</sup> day<sup>-1</sup>. One partial response was seen in a patient with heavily pretreated breast cancer (Punt *et al*, 2001). A second trial investigated an alternative schedule – a 1-h infusion administered every 3 weeks (Raymond *et al*, 2002). Toxicities were similar to the 5-day regimen and comprised myelosuppression, acne-like skin rash, alopecia, mucositis, conjunctivitis, hypoglycaemia, nausea and fatigue. Recommended doses were 700 mg m<sup>-2</sup> for the heavily pretreated group and 800 mg m<sup>-2</sup> for the lightly pretreated group. No partial responses were observed. A weekly 1-h infusion schedule for 4 consecutive weeks and a continuous 120-h infusion have also been evaluated with similar toxicities being observed. The recommended doses for the weekly and continuous infusion schedules were 400 and 96 mg m<sup>-2</sup>, respectively. Pharmacokinetic studies indicate that the clearance and volume of distribution at steady state of E7070 decrease with increasing dose.

Phase II single-agent studies are under way in a number of different tumour types investigating the once-every-3-weeks and daily-for-5-days schedules. In patients with fluorouracil refractory colorectal cancer, two of 21 patients receiving the once-every-4-weeks schedule, and two of 23 patients receiving the daily-for-5-days schedule, had objective responses, with 10 and 13% of patients, respectively, having stable disease at 6 months (Mainwaring *et al*, 2002). In a Phase II study of patients with NSCLC, who had previously received one chemotherapy regimen, only one of 44 patients had an objective response (Talbot *et al*, 2002). No objective responses were observed in patients with metastatic melanoma receiving a dose of 700 mg m<sup>-2</sup> for over 1 h every 3 weeks (Aamdal *et al*, 2002).

### R-Roscovotine (CYC202)

The purine analogue *R*-roscovotine (CYC202) is a highly selective, orally bioavailable, small molecule inhibitor of several Cdks competing with their ATP binding sites: it is a relatively potent inhibitor of human Cdk2/cyclin E, Cdk7/cyclin H, Cdk9/cyclin T1 with IC<sub>50</sub> of 0.1, 0.5 and 0.8 μM, respectively (Meijer *et al*, 1997), but inhibits Cdk4/cyclin D1 with an IC<sub>50</sub> of 14.2 μM. It has an average IC<sub>50</sub> against the NCI cell-line panel of 16 μM. It also blocks the degradation of p53 through the inhibition of MDM2 expression (Lu *et al*, 2001). CYC202 induces G<sub>1</sub> and G<sub>2</sub>/M arrest and cell death from all compartments of the cell cycle (Schutte *et al*, 1997; McClue *et al*, 2002). The antitumour efficacy of CYC202 has also been tested in a panel of human tumour xenografts (McClue *et al*, 2002). Continuous exposure to CYC202 at dosages ranging from 0.3 to 100 μM demonstrated dose-dependent antitumour activity.

Recent molecular pharmacology studies have shown that treatment of colorectal cancer cells with CYC202 results in a decrease in pRb phosphorylation (serines 780, 608, 807, 811 and Thr-821), indicative of direct Cdk2 inhibition (Whittaker *et al*, 2004). In addition, CYC202 causes a downregulation of various cyclins, including cyclin D1; this is likely to lead to a secondary inhibition of various cyclins, which would explain the reduced phosphorylation at multiple sites on RB that is seen at later time points.

CYC202 has been evaluated in Phase I clinical trials. Two such trials have recently been reported. In the first trial, CYC202 was administered orally, twice daily for 7 days out of every 21. In all, 19 patients were treated for a total of 36 cycles of CYC202. At 800 mg BD, DLTs comprising grade 3 skin rash and grade 4 hypokalaemia were observed. Other toxicities seen included reversible renal impairment, mild reversible transaminitis and emesis. MAG-3 studies indicated that the renal impairment was related to altered renal blood flow. No evidence of renal tubular damage was detected. The aetiology of these renal changes is unknown but could be related to the effects of CYC202 on adenosine receptors. The pharmacokinetics of the compound were dose proportional, with CYC202 being widely distributed (720.8 l, 95% CI 384.9–1056.8) and rapidly cleared (142.6 l/h, 95% CI 80.5–204.9) with a mean terminal elimination half-life of 4.02 h (95% CI 2.8–5.2).

This trial is still recruiting patients, but no objective responses have yet been seen (Benson *et al*, 2003; White *et al*, 2004).

In the second trial, a twice-daily-for-5-days schedule, administered every 3 weeks was evaluated. The maximum twice-daily dose achieved was 1600 mg BD with a recommended dose of 1250 mg BD. Toxicities reported have included grade 4 emesis, grade 3 asthenia and skin rash. No objective responses were seen but stable disease was recorded in three out of 29 patients treated. (Pierga *et al*, 2003) Exploration of a 10-day schedule is now under way.

### BMS-387032

High-throughput screening followed by lead optimisation has resulted in the identification of the 2-aminothiazole BMS-387032 as a potent, selective and competitive small molecule inhibitor of the Cdk2/cyclin E complex, with an IC<sub>50</sub> of 48 nM. The 2-aminothiazoles have been reported to be 10- and 30-fold more potent against Cdk2 than Cdk1 and Cdk4, and three to five orders of magnitude less potent against all other tested non-Cdk kinases. The X-ray crystal structure of this compound with Cdk2 has been reported, and has revealed the mechanisms by which this compound interacts with the Cdk2 ATP binding site (Misra *et al*, 2004). *In vitro*, BMS-387032 inhibits Cdk2 phosphorylation in the A2780 ovarian carcinoma cell line, inhibiting the phosphorylation of downstream targets of Cdk2 including pRb, histone H1 and DNA polymerase- $\alpha$ .

The compound displays potent *in vitro* cytotoxicity against the A2780 cell line with an IC<sub>50</sub> of 50 nM, and is active against a broad array of cell lines. *In vivo* studies have confirmed oral bioavailability and activity against a variety of cell lines, including P388 murine leukaemia, A2780 ovarian and A431 human squamous cell carcinoma. Combination studies indicate that BMS-387032 is synergistic with cisplatin in SV-1 colon carcinoma cells, this synergy being dependent on the drug sequence (Lane *et al*, 2003). Phase I clinical trials with BMS-387032 are ongoing utilising different schedules (Jones *et al*, 2003; McCormick *et al*, 2003; Shapiro *et al*, 2003).

### PHARMACODYNAMIC STUDIES

As with other molecularly targeted therapeutics under investigation, the clinical development of the Cdk inhibitors in early trials requires the study of their biological effects in tumour cells acquired through serial tumour biopsies. These studies are required to select optimal biological dosing and schedule, and identify the patient population most likely to benefit from these agents. Potential pharmacodynamic parameters under investigation include the inhibition of pRb phosphorylation; the depletion of cyclins and Cdks; increases in Cdk inhibitor protein expression; and the suppression of mdm2 expression and induction of p53 expression. Pharmacodynamic studies have been reported for

flavopiridol (Lam *et al*, 2001) and CYC202 (Whittaker *et al*, 2004). More recent studies indicate that <sup>18</sup>F-labelled 3'-deoxy-3'-fluorothymidine may be a useful imaging modality for the selective Cdk2 inhibitor BMS-387032 (Fischman *et al*, 2004). These translational studies are critically important in the optimal development of these agents.

### CONCLUDING REMARKS

Significant progress has been made in the clinical targeting of the Cdks. Newer and more specific Cdk inhibitors are envisioned to result in decreased toxicity and more selective cytotoxicity. Increased specificity may not, however, spare noncycling cells since recent data have implicated the Cdks 5, 7, 8 and 9 in cellular functions that do not involve the cell cycle. Cdks 7, 8 and 9 have been reported to regulate RNA transcription through the phosphorylation of RNA polymerase II, while Cdk5 has been shown to be involved in regulating insulin secretion, synaptic vesicle recycling, neuronal survival and tau (microtubule associated protein) phosphorylation and aggregation (Sausville, 2002). These findings may explain why hyperglycaemia has been observed with many chemical Cdk inhibitors. The RNA polymerase II regulatory activity of Cdk 7, 8 and 9 may, however, enhance the antitumour effect of these agents, and it has indeed been suggested that the anticancer activity of flavopiridol may be in part related to the inhibition of RNA transcription. It remains to date unclear whether the inhibition of Cdk 7, 8 and 9 activity is desirable for an anticancer agent, or whether the toxicity associated with inhibiting these noncycling Cdks will substantially decrease cytotoxic selectivity and the therapeutic index.

Overall, these data suggest that highly selective small molecule inhibitors of specific Cdks may be preferable in order to decrease toxicity. Generating this specificity, however, not only remains a significant challenge to chemists but may also decrease anticancer efficacy in view of the inherent functional redundancy of this family of kinases. A broader-spectrum inhibitor that can, for example, selectively inhibit Cdk1, Cdk2, Cdk4 and Cdk6 at low nanomolar IC<sub>50</sub> concentrations may therefore be preferable. The recent observations that selectively inhibiting Cdk2 in certain cell lines is not sufficient for antitumour activity would support this view (Tetsu and McCormick, 2003), as would the demonstration that the Cdk2 knockout mouse shows no major abnormalities and in particular no effects on proliferation (Ortega *et al*, 2003). The high sequence homology of the ATP binding sites of these and the noncycling kinases Cdk 5, 7, 8 and 9, as well as that of glycogen synthase kinase-3 $\beta$  and that of the adenosine receptors makes this a difficult task. However, much has already been achieved and while many questions need to be answered we are moving closer to the Holy Grail: the development of compounds selectively cytotoxic to tumour cells, yet sparing normal cells.

### REFERENCES

- Aamdal S, Smyth J, Awada A, Dittrich C, Caponigro F, Djurasinovic N, Marchal B, Yule M (2002) Phase II study of E7070 in patients with metastatic melanoma (stage IV). *Eur J Cancer* **38**: S50
- Akiyama T, Yoshida T, Tsujita T, Shimizu M, Mizukami T, Okabe M, Akinaga S (1997) G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sd1 in p53-mutated human epidermoid carcinoma A431 cells. *Cancer Res* **57**: 1495–1501
- Arguello F, Alexander M, Sterry JA, Tudor G, Smith EM, Kalavar NT, Greene Jr JF, Koss W, Morgan CD, Stinson SF, Siford TJ, Alvord WG, Klabansky RL, Sausville EA (1998) Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity *in vivo* against human leukemia and lymphoma xenografts. *Blood* **91**: 2482–2490
- Bennett P, Mani S, O'Reilly S, Wright J, Schilsky RL, Vokes EE, Grochow L (1999) Phase II trial of flavopiridol in metastatic colorectal cancer: preliminary results. *Proc Am Soc Clin Oncol* **18**: 277
- Benson C, White J, Twelves C, O'Donnell A, Cruickshank C, Tan S, Gianella-Borradori A, Judson I (2003) A phase I trial of the oral cyclin dependent kinase inhibitor CYC202 in patients with advanced malignancy. *Proc Am Soc Clin Oncol* **22**: 209
- Bible KC, Kaufmann SH (1997) Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. *Cancer Res* **57**: 3375–3380

- Bunch RT, Eastman A (1997) 7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells. *Cell Growth Differ* 8: 779–788
- Burdette-Radoux S, Tozer R, Lohmann R, Quirt I, Ernst D, Walsh W, Wainman N, Colevas D, Eisenhauer E (2002) A. NCIC CTG phase II study of flavopiridol in patients with previously untreated metastatic malignant melanoma. *Proc Am Soc Clin Oncol* 21: 346
- Busby EC, Leistriz DF, Abraham RT, Karnitz LM, Sarkaria JN (2000) The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. *Cancer Res* 60: 2108–2118
- Carlson B, Lahusen T, Singh S, Loaiza-Perez A, Worland PJ, Pestell R, Albanese C, Sausville EA, Senderowicz AM (1999) Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. *Cancer Res* 59: 4634–4641
- Fischman A, Letrent S, Bonab A, Livni E, Carter E, Rubin R, Mauro D, Tarby C, Galbraith S, Griffin T (2004) PET as a biomarker of the antitumor effects of the CDK2 inhibitor BMS-387032. *Proc Am Soc Clin Onc* 23: 135
- Fuse E, Tani H, Kurata N, Kobayashi H, Shimada Y, Tamura T, Sasaki Y, Tanigawara Y, Lush RD, Headlee D, Figg WD, Arbusk SG, Senderowicz AM, Sausville EA, Akinaga S, Kuwabara T, Kobayashi S (1998) Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. *Cancer Res* 58: 3248–3253
- Jones S, Burris H, Kies M, Willcutt N, Degen P, Woo M, Letrent S, Youssoufian H, DeCiliis A, Papadimitrakopoulou V (2003) A Phase I study to determine the safety and pharmacokinetics (PK) of BMS-387032 given intravenously every three weeks in patients with metastatic refractory solid tumors. *Proc Am Soc Clin Oncol* 22: 199
- Kahn ME, Senderowicz A, Sausville EA, Barrett KE (2001) Possible mechanisms of diarrheal side effects associated with the use of a novel chemotherapeutic agent, flavopiridol. *Clin Cancer Res* 7: 343–349
- Kouroukis CT, Belch A, Crump M, Eisenhauer EA, Gascoyne RD, Meyer R, Lohmann R, Lopez P, Powers J, Turner R, Connors JM (2003) Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 21: 1740–1745
- Lam LT, Pickeral OK, Peng AC, Rosenwald A, Hurt EM, Giltman JM, Averett LM, Zhao H, Davis RE, Sathyamoorthy M, Wahl LM, Harris ED, Mikovits JA, Monks AP, Hollingshead MG, Sausville EA, Staudt LM (2001) Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. *Genome Biol* 2(10): 41.1–41.11
- Lane M, Temple K, Yu B, Nguyen H, Wadler S (2003) Combined treatment with cisplatin and a novel cdk2 specific inhibitor (BMS 387032), results in cytotoxic synergy in human colon carcinoma cells that is dependent on dose, sequence and cyclin D1 expression. *Proc Am Assoc Can Res* 44: 161
- Lin TS, Dalton JT, Wu D, Fischer B, Moran M, Lucas D, Cunningham K, Colevas AD, Grever MR, Byrd JC (2004) Flavopiridol given as a 30-min intravenous (IV) bolus followed by 4-h continuous IV infusion (CIVI) results in clinical activity and tumor lysis in refractory chronic lymphocytic leukemia (CLL). *J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition)*. Vol 22, No 14S (July 15 Supplement), 2004: 6564
- Lin TS, Howard OM, Neuberger DS, Kim HH, Shipp MA (2002) Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma. *Leukemia Lymphoma* 43: 793–797
- Lu W, Chen L, Peng Y, Chen J (2001) Activation of p53 by roscovitine-mediated suppression of MDM2 expression. *Oncogene* 20: 3206–3216
- Mainwaring P, Van Cutsem E, Van Laetham J-L, Propper D, Twelves C, Bridgewater J, Audhuy B, Carmichael J, Punt C, Cassidy J, Stuart N, Ravic M (2002) A multicentre randomised phase II study of E7070 in patients with colorectal cancer who have failed 5-fluorouracil-based chemotherapy. *Proc Am Soc Clin Oncol* 21: 153
- McClue SJ, Blake D, Clarke R, Cowan A, Cummings L, Fischer PM, MacKenzie M, Melville J, Stewart K, Wang S, Zhelev N, Zheleva D, Lane DP (2002) *In vitro* and *in vivo* antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). *Int J Cancer* 102: 463–468
- McCormick J, Gadgeel S, Helmke W, Chaplen R, van Leeuwen B, Woo M, Youssoufian H, DeCiliis A, Letrent S, LoRusso P (2003) Phase I study of BMS-387032, a cyclin dependent kinase (CDK) 2 inhibitor. *Proc Am Soc Clin Oncol* 22: 208
- Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, Inagaki M, Delcross JG, Moulinoux JP (1997) Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. *Eur J Biochem* 243: 527–536
- Messmann RA, Ullmann CD, Lahusen T, Kalehua A, Wasfy J, Melillo G, Ding I, Headlee D, Figg WD, Sausville EA, Senderowicz AM (2003) Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6. *Clin Cancer Res* 9: 562–570
- Misra RN, Xiao HY, Kim KS, Lu S, Han WC, Barbosa SA, Hunt JT, Rawlins DB, Shan W, Ahmed SZ, Qian L, Chen BC, Zhao R, Bednarz MS, Kellar KA, Mulheron JG, Batorsky R, Roongta U, Kamath A, Marathe P, Ranadive SA, Sack JS, Tokarski JS, Pavletich NP, Lee FY, Webster KR, Kimball SD (2004) N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]-methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. *J Med Chem* 47(7): 1719–1728
- Motwani M, Jung C, Sirotiak FM, She Y, Shah MA, Gonen M, Schwartz GK (2001) Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. *Clin Cancer Res* 7: 4209–4219
- Ortega S, Prieto I, Odajima J, Martin A, Dubus P, Sotillo R, Barbero JL, Malumbres M, Barbacid M (2003) Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. *Nat Genet* 35(1): 25–31
- Ozawa Y, Sugi NH, Nagasu T, Owa T, Watanabe T, Koyanagi N, Yoshino H, Kitoh K, Yoshimatsu K (2001) E7070, a novel sulphonamide agent with potent antitumor activity *in vitro* and *in vivo*. *Eur J Cancer* 37: 2275–2282
- Patel V, Senderowicz AM, Pinto Jr D, Igishi T, Raffeld M, Quintanilla-Martinez L, Ensley JF, Sausville EA, Gutkind JS (1998) Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. *J Clin Invest* 102: 1674–1681
- Pierga J, Faivre S, Vera K, Laurence V, Delbaldo C, Bekradda M, Armand JP, Gianella-Borradori A, Dieras V, Raymond E (2003) A phase I and pharmacokinetic (PK) trial of CYC202, a novel oral cyclin-dependent kinase (CDK) inhibitor, in patients (pts) with advanced solid tumors. *Proc Am Soc Clin Oncol* 22: 210
- Punt CJ, Fumoleau P, van de WB, Faber MN, Ravic M, Campone M (2001) Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-Early Clinical Studies Group (ECSG). *Ann Oncol* 12: 1289–1293
- Raymond E, Bokkel Huinink WW, Taieb J, Beijnen JH, Faivre S, Wanders J, Ravic M, Fumoleau P, Armand JP, Schellens JH (2002) Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer. *J Clin Oncol* 20: 3508–3521
- Sato S, Fujita N, Tsuruo T (2002) Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). *Oncogene* 21(21): 1727–1738
- Sausville EA (2002) Complexities in the development of cyclin-dependent kinase inhibitor drugs. *Trends Mol Med* 8(4 Suppl): S32–S37, Review
- Sausville EA, Arbusk SG, Messmann R, Headlee D, Bauer KS, Lush RM, Murgo A, Figg WD, Lahusen T, Jaken S, Jing X, Roberge M, Fuse E, Kuwabara T, Senderowicz AM (2001) Phase I trial of 72-h continuous infusion UCN-01 in patients with refractory neoplasms. *J Clin Oncol* 19: 2319–2333
- Sausville EA, Lush RD, Headlee D, Smith AC, Figg WD, Arbusk SG, Senderowicz AM, Fuse E, Tani H, Kuwabara T, Kobayashi S (1998) Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models. *Cancer Chemother Pharmacol* 42(Suppl): S54–S59
- Schutte B, Nieland L, van Engeland M, Henfling ME, Meijer L, Ramaekers FC (1997) The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics. *Exp Cell Res* 236: 4–15
- Schwartz GK, Ilson D, Saltz L, O'Reilly E, Tong W, Maslak P, Werner J, Perkins P, Stoltz M, Kelsen D (2001) Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. *J Clin Oncol* 19: 1985–1992
- Schwartz GK, O'Reilly E, Ilson D, Saltz L, Sharma S, Tong W, Maslak P, Stoltz M, Eden L, Perkins P, Endres S, Barazzoul J, Spriggs D, Kelsen D (2002) Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. *J Clin Oncol* 20: 2157–2170

- Senderowicz AM (2003) Small-molecule cyclin-dependent kinase modulators. *Oncogene* **22**: 6609–6620
- Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L, Hill K, Steinberg SM, Figg WD, Tompkins A, Arbusk SG, Sausville EA (1998) Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. *J Clin Oncol* **16**: 2986–2999
- Senderowicz AM, Sausville EA (2000) Preclinical and clinical development of cyclin-dependent kinase modulators. *J Natl Cancer Inst* **92**: 376–387
- Shapiro G, Lewis N, van Leeuwen B, Letrent S, Woo M, Youssoufian H, DeCiliis A, Cohen R (2003) A Phase I study to determine the safety and pharmacokinetics (PK) of BMS-387032 with a 24-h infusion given every three weeks in patients with metastatic refractory solid tumors. *Proc Am Soc Clin Oncol* **22**: 199
- Shapiro GL, Supko JG, Patterson A, Lynch C, Lucca J, Zaccarola PF, Muzikansky A, Wright JJ, Lynch Jr TJ, Rollins BJ (2001) A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. *Clin Cancer Res* **7**: 1590–1599
- Stadler WM, Vogelzang NJ, Amato R, Sosman J, Taber D, Liebowitz D, Vokes EE (2000) Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium Study. *J Clin Oncol* **18**: 371–375
- Talbot D, Norbury C, Slade M, von Pawel J, Bosquee L, Gatzemeier U, Ravic M (2002) A phase II and pharmacodynamic study of E7070 in patients with non-small cell lung cancer (NSCLC) who have failed platinum-based chemotherapy. *Proc Am Soc Clin Oncol* **21**: 327
- Tan AR, Headlee D, Messmann R, Sausville EA, Arbusk SG, Murgo AJ, Melillo G, Zhai S, Figg WD, Swain SM, Senderowicz AM (2002) Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-h infusion in patients with advanced neoplasms. *J Clin Oncol* **20**: 4074–4082
- Tetsu O, McCormick F (2003) Proliferation of cancer cells despite CDK2 inhibition. *Cancer Cell* **3**(3): 233–245
- Thomas JP, Tutsch KD, Cleary JF, Bailey HH, Arzooonian R, Alberti D, Simon K, Feierabend C, Binger K, Marnocha R, Dresen A, Wilding G (2002) Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. *Cancer Chemother Pharmacol* **50**: 465–472
- Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O'Connor PM (1996) UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. *J Natl Cancer Inst* **88**: 956–965
- White JD, Cassidy J, Tweleves C, Benson C, Pacey S, Judson I, McGrath H, Rose F, Frenz L (2004) Phase I trial of the oral cyclin dependent kinase inhibitor CYC202 in patients with advanced malignancy. *Proc Am Soc Clin Oncol* **23**: 205
- Whittaker SR, Walton MI, Garrett MD, Workman P (2004) The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits RB phosphorylation, causes loss of cyclin D1 and activates the mitogen activated protein kinase pathway. *Cancer Res* **64**(14): 262–272
- Wittmann S, Bali P, Donapaty S, Nimmanapalli R, Guo F, Yamaguchi H, Huang M, Jove R, Wang HG, Bhalla K (2003) Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. *Cancer Res* **63**: 93–99
- Yu Q, La Rose J, Zhang H, Takemura H, Kohn KW, Pommier Y (2002) UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G (2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. *Cancer Res* **62**(20): 5743–5748